The IRA explicitly excludes from price negotiation orphan drugs designated for only one rare disease or condition and for which the only active approved indication is for such disease or condition. Those drugs with multiple orphan designations are not excluded from drug price negotiation. As we are developing bexotegrast in multiple orphan indications and may seek obtain orphan drug designation for other product candidates, this aspect of the IRA could have a negative impact on our ability to rely on the orphan drug exclusion to the “maximum fair price”.
All entries for: Pliant Therapeutics
May 8, 2025
Pliant Therapeutics
Negative Outlook
South San Francisco, CA
51-200 employees
Disease Area: Chronic Disease, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
May 5, 2025
Pliant Therapeutics
Layoffs
South San Francisco, CA
51-200 employees
About two months after discontinuing the Phase IIb/III BEACON-IPF study of idiopathic pulmonary fibrosis drug candidate bexotegrast, Pliant Therapeutics announced it’s cutting roughly 45% of its workforce. The move is meant to help extend the San Francisco–based biotech’s cash runway to support execution of late-stage clinical trials. The company, which develops oral integrin inhibitors for fibrotic diseases, did not say how long that runway will last.
Disease Area: Chronic Disease, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule